e-learning | Ertugliflozin in type 2 diabetes and the other SGLT-2 inhibitors

20th September 2019 by Louise Hudman

e-learning | Ertugliflozin in type 2 diabetes and the other SGLT-2 inhibitors

This is a new guideline from NICE giving advice on ertugliflozin, published in April 2019. I am also doing a quick reminder about the other SGLT-2 inhibitors.

What is ertugliflozin?

It is another sodium-glucose co-transporter 2 (SGLT-2) inhibitor, like canagliflozin, dapagliflozin and empagliflozin.

It is thought to be as effective as the other SGLT-2 inhibitors, but it is cheaper.

Join

Join to view the rest of this content, as well as access all the benefits of joining NASGP.

Join

Login

Already a member? Login to view this content.

Login

Related content

"I started working as a locum GP in January this year and NASGP have been invaluable in helping to co-ordinate my bookings and organise all the administrative aspects of sessional work which can be complex and time consuming. Their client support is outstanding and they have always resolved any queries promptly and personally. They care about the service they provide and I would not hesitate to recommend them to any sessional GPs who want to minimise time spent on administration and focus on providing patients with high quality care."

Dr Paul Riley, Locum GP

Dr Paul Riley, Locum GP

See the full list of features within our NASGP membership plans

Membership